Accessibility Menu
Pacific Biosciences Of California logo

Pacific Biosciences Of California

(NASDAQ) PACB

Current Price$1.41
Market Cap$401.66M
Since IPO (2010)-92%
5 Year-96%
1 Year+12%
1 Month-11%

Pacific Biosciences Of California Financials at a Glance

Market Cap

$401.66M

Revenue (TTM)

$160.00M

Net Income (TTM)

$546.38M

EPS (TTM)

$-1.83

P/E Ratio

-0.72

Dividend

$0.00

Beta (Volatility)

2.40 (High)

Price

$1.41

Volume

186,578

Open

$1.32

Previous Close

$1.41

Daily Range

$1.29 - $1.42

52-Week Range

$0.85 - $2.73

PACB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pacific Biosciences Of California

Industry

Life Sciences Tools and Services

Employees

485

CEO

Christian O. Henry, MBA

Headquarters

Menlo Park, CA 94025, US

PACB Financials

Key Financial Metrics (TTM)

Gross Margin

28%

Operating Margin

-3%

Net Income Margin

-3%

Return on Equity

-213%

Return on Capital

-76%

Return on Assets

-70%

Earnings Yield

-1.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$401.66M

Shares Outstanding

302.00M

Volume

186.58K

Short Interest

0.00%

Avg. Volume

7.11M

Financials (TTM)

Gross Profit

$50.67M

Operating Income

$557.56M

EBITDA

$34.20M

Operating Cash Flow

$111.21M

Capital Expenditure

$2.71M

Free Cash Flow

$113.92M

Cash & ST Invst.

$279.51M

Total Debt

$759.46M

Pacific Biosciences Of California Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$44.65M

+13.8%

Gross Profit

$16.75M

+66.5%

Gross Margin

37.52%

N/A

Market Cap

$401.66M

N/A

Market Cap/Employee

$698.53K

N/A

Employees

575

N/A

Net Income

$40.37M

-1802.7%

EBITDA

$38.43M

-334.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$479.96M

-69.9%

Accounts Receivable

$35.45M

+28.8%

Inventory

$49.28M

-16.1%

Long Term Debt

$759.46M

+14.7%

Short Term Debt

$448.00K

-95.5%

Return on Assets

-69.68%

N/A

Return on Invested Capital

-75.90%

N/A

Free Cash Flow

$24.93M

+22.7%

Operating Cash Flow

$19.07M

+37.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNAGinkgo Bioworks Holdings, Inc.
$6.91+6.47%
OFIXOrthofix Medical Inc.
$11.70-1.35%
FLGTFulgent Genetics, Inc.
$15.56+2.77%
SIBNSI-BONE, Inc.
$12.77-0.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.35+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%
RIVNRivian Automotive
$16.12+0.04%

Questions About PACB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.